Current market size is approx. $800M annually and growing
Itch is #1 reason for canine veterinarian visits
have atopic dermatitis, an allergic skin disease
Key Profit Center
of dogs seen by dermatologists suffer from from pruritis (itch)
increase in itchy dog veterinarian visits since 2014
KindredBio is pursuing a multi-pronged approach toward atopic dermatitis.
KindredBio reported positive topline results from its pilot field effectiveness study of tirnovetmab (KIND-016), a fully caninized, high-affinity monoclonal antibody targeting interleukin-31, for the treatment of atopic dermatitis in dogs. We plan to begin a pivotal study in the fourth quarter of 2020.
We reported positive results from our pilot laboratory study of our interleukin-4R molecule, including evidence of positive efficacy and dose response. A second pilot study to further assess efficacy and dosing is planned for 3Q 2020.
The company reported positive results from its pilot efficacy study of its canine IL-4/13 SINK molecule in the first quarter of 2020. An initial pilot study for IL-17 has also been completed and the molecule was well-tolerated. Both programs are currently on hold pending further funding or partnering capital.
“Itch associated with Atopic Dermatitis may be caused by either neurogenic, inflammatory and/or behavioral pathomechanisms. I often find that I need to address a combination of pathways to successfully control itch in my atopic patients.”